🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are escalating globally, with figures suggesting more than 82 million instances annually. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This approval marks a major breakthrough in the management of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Results and Worldwide Availability

As per results released by a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which involves an injection and a pill. The research enrolled hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have shared hope. Having a one-pill regimen of this kind is seen as a "game-changer" for gonorrhoea control. This is viewed as essential to lessen the impact of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.